AB-2100

PreclinicalBiologic

AArsenal Biosciences, Inc.

AB-2100 is one of 17 biologic programs targeting Clear Cell Renal Cell Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Clear Cell Renal Cell CarcinomaActive, not recruiting

Clear Cell Renal Cell CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

19 competitors in Clear Cell Renal Cell Carcinoma

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 3

4 2

Keytruda

Merck & Co.

Phase 3

4 3

Cabometyx

Bristol-Myers Squibb

Phase 3

3 4

Votrient

Novartis

Phase 3

1 5

Adavosertib

AstraZeneca

Phase 2

1 6

M6620

AstraZeneca

Phase 2

1 7

Inlyta

PPrism Pharmaceuticals

Phase 2

2 8

Navmi

SSummit Therapeutics

Phase 2

1 9

Welireg

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 10

Zanzalintinib

Merck & Co.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalActive, not recruiting

Clear Cell Renal Cell Carcinoma

NCT06245915

Clinical

Trials by Indication[1]

Clear Cell Renal Cell Carcinoma1 trial

An Open-label, Multicenter Phase 1/2 Study to Evaluate the Safety and Efficacy of AB-2100 in Patients With Recurrent Advanced or Metastatic Clear-cell Renal Cell Carcinoma (ccRCC)

Active, not recruiting·AArsenal Biosciences, Inc.·Preclinical·NCT06245915·37 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AB-2100. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AB-2100 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AB-2100. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Arsenal Biosciences, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: AArsenal Biosciences, Inc.

AB-2100

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Clear Cell Renal Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News